Truncated and modified amyloid-beta species

Alzheimer's Research and Therapy
6, 28
DOI: 10.1186/alzrt258

Citation Report

#	Article	IF	Citations
1	Proteomics of protein post-translational modifications implicated in neurodegeneration. Translational Neurodegeneration, 2014, 3, 23.	3.6	59
2	A20 suppresses vascular inflammation by recruiting proinflammatory signaling molecules to intracellular aggresomes. FASEB Journal, 2015, 29, 1869-1878.	0.2	13
3	Chloroquine and Chloroquinoline Derivatives as Models for the Design of Modulators of Amyloid Peptide Precursor Metabolism. ACS Chemical Neuroscience, 2015, 6, 559-569.	1.7	35
4	Decrease in APP and CP mRNA expression supports impairment of iron export in Alzheimer's disease patients. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 2116-2122.	1.8	33
5	Amyloid-Î² as a biomarker for Alzheimerâ€™s disease: quantification methods in body fluids. Expert Review of Proteomics, 2015, 12, 343-354.	1.3	27
6	Analyzing dendritic spine pathology in Alzheimerâ€™s disease: problems and opportunities. Acta Neuropathologica, 2015, 130, 1-19.	3.9	154
7	Extracellular Vesicles in Alzheimerâ€™s Disease: Friends or Foes? Focus on AÎ²-Vesicle Interaction. International Journal of Molecular Sciences, 2015, 16, 4800-4813.	1.8	73
8	Identification of amyloid beta mid-domain fragments in human cerebrospinal fluid. Biochimie, 2015, 113, 86-92.	1.3	8
9	Cellular Functions of the Amyloid Precursor Protein from Development to Dementia. Developmental Cell, 2015, 32, 502-515.	3.1	191
10	Neuroinflammation in Alzheimer's disease. Lancet Neurology, The, 2015, 14, 388-405.	4.9	4,129
11	Linking Genes to Neurological Clinical Practice. Journal of Neurologic Physical Therapy, 2015, 39, 52-61.	0.7	16
12	Truncated Amyloid-Î²(11â€“40/42) from Alzheimer Disease Binds Cu2+ with a Femtomolar Affinity and Influences Fiber Assembly. Journal of Biological Chemistry, 2015, 290, 27791-27802.	1.6	53
13	Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models. Acta Neuropathologica, 2015, 130, 713-729.	3.9	53
14	Reduction of amyloid-beta levels in mouse eye tissues byÂintra-vitreally delivered neprilysin. Experimental Eye Research, 2015, 138, 134-144.	1.2	36
15	Isobaric Quantification of Cerebrospinal Fluid Amyloid-Î² Peptides in Alzheimerâ€™s Disease: C-Terminal Truncation Relates to Early Measures of Neurodegeneration. Journal of Proteome Research, 2015, 14, 4834-4843.	1.8	7
16	Beta Amyloid Peptides: Extracellular and Intracellular Mechanisms of Clearance in Alzheimerâ€™s Disease. , 0, , .		4
17	Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies?. Current Alzheimer Research, 2016, 13, 1145-1164.	0.7	50
18	Evidence For and Against a Pathogenic Role of Reduced Î³-Secretase Activity in Familial Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 52, 781-799.	1.2	44

#	Article	IF	Citations
19	Kinetic and structural characterization of amyloidâ€Î²2 peptide hydrolysis by human angiotensinâ€1â€converting enzyme. FEBS Journal, 2016, 283, 1060-1076.	2.2	19
20	TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. Journal of Experimental Medicine, 2016, 213, 667-675.	4.2	565
21	Amyloid Î²-peptides interfere with mitochondrial preprotein import competence by a coaggregation process. Molecular Biology of the Cell, 2016, 27, 3257-3272.	0.9	87
22	Kinetics of the Interactions between Copper and Amyloidâ€Î²2 with FAD Mutations and Phosphorylation at the Nâ€...terminus. ChemBioChem, 2016, 17, 1732-1737.	1.3	15
23	Mice are not Men: ADAM30 Findings Emphasize a Broader Look Towards Murine Alzheimer's Disease Models. EBioMedicine, 2016, 9, 19-20.	2.7	0
24	Interplay of histidine residues of the Alzheimerâ€™s disease AÎ² peptide governs its Zn-induced oligomerization. Scientific Reports, 2016, 6, 21734.	1.6	81
25	An Account of Amyloid Oligomers: Facts and Figures Obtained from Experiments and Simulations. ChemBioChem, 2016, 17, 657-676.	1.3	95
26	Amyloid Plaque in the Human Brain Can Decompose from AÎ²(1-40/1-42) by Spontaneous Nonenzymatic Processes. Analytical Chemistry, 2016, 88, 2675-2684.	3.2	32
27	Recent progress in translational research on neurovascular and neurodegenerative disorders. Restorative Neurology and Neuroscience, 2017, 35, 87-103.	0.4	16
28	Effects of Intrinsic and Extrinsic Factors on Aggregation of Physiologically Important Intrinsically Disordered Proteins. International Review of Cell and Molecular Biology, 2017, 329, 145-185.	1.6	17
29	Therapeutic potential of nuclear receptor agonists in Alzheimer's disease. Journal of Lipid Research, 2017, 58, 1937-1949.	2.0	61
30	Intracerebroventricular injection of beta-amyloid in mice is associated with long-term cognitive impairment in the modified hole-board test. Behavioural Brain Research, 2017, 324, 15-20.	1.2	25
31	Posttranslational modification impact on the mechanism by which amyloidâ€Î²2 induces synaptic dysfunction. EMBO Reports, 2017, 18, 962-981.	2.0	50
32	Multiple functions of insulin-degrading enzyme: a metabolic crosslight?. Critical Reviews in Biochemistry and Molecular Biology, 2017, 52, 554-582.	2.3	73
33	Nâ€Terminally Truncated Amyloidâ€Î²2_(11â€“40/42) Cofibrillizes with its Fullâ€Length Counterpart: Implications for Alzheimer's Disease. Angewandte Chemie - International Edition, 2017, 56, 9816-9819.	7.2	25
34	Glutaminyl cyclase activity correlates with levels of AÎ² peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimerâ€™s disease patients. Alzheimer's Research and Therapy, 2017, 9, 38.	3.0	24
35	Emerging roles for the amyloid precursor protein and derived peptides in the regulation of cellular and systemic metabolism. Journal of Neuroendocrinology, 2017, 29, .	1.2	15
36	Preclinical to phase II amyloid beta (A_{Î²}) peptide modulators under investigation for Alzheimerâ€™s disease. Expert Opinion on Investigational Drugs, 2017, 26, 579-592.	1.9	23

#	Article	IF	Citations
37	Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid Î² Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimerâ€™s Disease Model Mice. ACS Chemical Neuroscience, 2017, 8, 454-459.	1.7	8
38	Pyroglutamateâ€Modified Amyloid Î² (11â€•40) Fibrils Are More Toxic than Wildtype Fibrils but Structurally Very Similar. Chemistry - A European Journal, 2017, 23, 15834-15838.	1.7	17
39	Diversity of Amyloid-beta Proteoforms in the Alzheimerâ€™s Disease Brain. Scientific Reports, 2017, 7, 9520.	1.6	125
40	N-Terminal Acetylation Preserves Î±-Synuclein from Oligomerization by Blocking Intermolecular Hydrogen Bonds. ACS Chemical Neuroscience, 2017, 8, 2145-2151.	1.7	52
41	Nâ€Terminally Truncated Amyloidâ€Î² (11 â€“ 40/42) Cofibrillizes with its Fullâ€Length Counterpart: Implications for Alzheimer's Disease. Angewandte Chemie, 2017, 129, 9948-9951.	1.6	7
42	Dimerization of the transmembrane domain of amyloid precursor protein is determined by residues around the Î³-secretase cleavage sites. Journal of Biological Chemistry, 2017, 292, 15826-15837.	1.6	26
43	APP/AÎ² structural diversity and Alzheimer's disease pathogenesis. Neurochemistry International, 2017, 110, 1-13.	1.9	78
44	Filling the void: a role for exercise-induced BDNF and brain amyloid precursor protein processing. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2017, 313, R585-R593.	0.9	25
45	Phosphorylation of a full length amyloid-Î² peptide modulates its amyloid aggregation, cell binding and neurotoxic properties. Molecular BioSystems, 2017, 13, 1545-1551.	2.9	24
46	Methodological approaches and insights on protein aggregation in biological systems. Expert Review of Proteomics, 2017, 14, 55-68.	1.3	2
47	Amyloid Î² Modification: A Key to the Sporadic Alzheimer's Disease?. Frontiers in Genetics, 2017, 8, 58.	1.1	52
48	Non-aggregated AÎ²25-35 Upregulates Primary Astrocyte Proliferation In Vitro. Frontiers in Cellular Neuroscience, 2017, 11, 301.	1.8	3
49	Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2017, 9, 62.	3.0	62
50	N-truncated AÎ²4â€“x peptides in sporadic Alzheimerâ€™s disease cases and transgenic Alzheimer mouse models. Alzheimer's Research and Therapy, 2017, 9, 80.	3.0	34
51	Dynamic changes of oligomeric amyloid Î² levels in plasma induced by spiked synthetic AÎ²42. Alzheimer's Research and Therapy, 2017, 9, 86.	3.0	57
52	Alzheimerâ€™s Disease as the Product of a Progressive Energy Deficiency Syndrome in the Central Nervous System: The Neuroenergetic Hypothesis. Journal of Alzheimer's Disease, 2017, 60, 1223-1229.	1.2	32
53	Type 2 diabetes mellitus in the pathophysiology of Alzheimer's disease. Dementia E Neuropsychologia, 2017, 11, 105-113.	0.3	34
54	APP deficiency results in resistance to obesity but impairs glucose tolerance upon high fat feeding. Journal of Endocrinology, 2018, 237, 311-322.	1.2	13

#	Article	IF	Citations
55	The receptor for advanced glycation endproducts is a mediator of toxicity by IAPP and other proteotoxic aggregates: Establishing and exploiting common ground for novel amyloidosis therapies. Protein Science, 2018, 27, 1166-1180.	3.1	19
56	Recent advances in the neurobiology and neuropharmacology of Alzheimerâ€™s disease. Biomedicine and Pharmacotherapy, 2018, 98, 297-307.	2.5	110
57	Decreased cerebral Irpâ€1B limits impact of social isolation in wild type and Alzheimer's disease modeled in Drosophila melanogaster. Genes, Brain and Behavior, 2018, 17, e12451.	1.1	5
58	Profiles of Î²-Amyloid Peptides and Key Secretases in Brain Autopsy Samples Differ with Sex and APOE Îµ4 Status: Impact for Risk and Progression of Alzheimer Disease. Neuroscience, 2018, 373, 20-36.	1.1	45
59	Direct Evidence of the Presence of Cross-Linked AÎ² Dimers in the Brains of Alzheimerâ€™s Disease Patients. Analytical Chemistry, 2018, 90, 4552-4560.	3.2	37
60	Amyloid-Î² and tau complexity â€" towards improved biomarkers and targeted therapies. Nature Reviews Neurology, 2018, 14, 22-39.	4.9	303
61	Resveratrol and Alzheimer's disease. From molecular pathophysiology to clinical trials. Experimental Gerontology, 2018, 113, 36-47.	1.2	41
62	AÎ² and the dementia syndrome: Simple versus complex perspectives. European Journal of Clinical Investigation, 2018, 48, e13025.	1.7	11
63	The antimicrobial protection hypothesis of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 1602-1614.	0.4	305
64	Rodent models for Alzheimer disease. Nature Reviews Neuroscience, 2018, 19, 583-598.	4.9	240
65	Passive AÎ² Immunotherapy: Current Achievements and Future Perspectives. Molecules, 2018, 23, 1068.	1.7	41
66	Targeting Amyloid Aggregation: An Overview of Strategies and Mechanisms. International Journal of Molecular Sciences, 2018, 19, 2677.	1.8	103
67	Phosphorylation of the Amyloid-Beta Peptide Inhibits Zinc-Dependent Aggregation, Prevents Na,K-ATPase Inhibition, and Reduces Cerebral Plaque Deposition. Frontiers in Molecular Neuroscience, 2018, 11, 302.	1.4	33
68	Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease. Frontiers in Neuroscience, 2018, 12, 254.	1.4	17
69	Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation. Molecules, 2018, 23, 924.	1.7	14
70	Modified amyloid variants in pathological subgroups of Î²â€amyloidosis. Annals of Clinical and Translational Neurology, 2018, 5, 815-831.	1.7	18
71	The Properties of Amyloid-Î² Fibrils Are Determined by their Path of Formation. Journal of Molecular Biology, 2018, 430, 1940-1949.	2.0	17
72	Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2018, 6, 3.	2.4	69

#	Article	IF	Citations
73	An inorganic overview of natural AÎ² fragments: Copper(II) and zinc(II)-mediated pathways. Coordination Chemistry Reviews, 2018, 369, 1-14.	9.5	14
74	The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta (AÎ²) species on long-term potentiation (LTP). Neuropharmacology, 2018, 140, 184-192.	2.0	22
75	Differential Modulation of the Aggregation of Nâ€Terminal Truncated AÎ² using Cucurbiturils. Chemistry - A European Journal, 2018, 24, 13647-13653.	1.7	19
76	Effect of ferric citrate on amyloidâ€beta peptides behavior. Biopolymers, 2018, 109, e23224.	1.2	11
77	Transthyretin Interferes with AÎ² Amyloid Formation by Redirecting Oligomeric Nuclei into Non-Amyloid Aggregates. Journal of Molecular Biology, 2018, 430, 2722-2733.	2.0	23
78	Investigation of plasma metabolomics and neurotransmitter dysfunction in the process of Alzheimer's disease rat induced by amyloid beta 25-35. RSC Advances, 2019, 9, 18308-18319.	1.7	5
79	Cu^{II} Binding Properties of N-Truncated AÎ² Peptides: In Search of Biological Function. Inorganic Chemistry, 2019, 58, 13561-13577.	1.9	34
80	Structure of amyloid-Î² (20-34) with Alzheimerâ€™s-associated isomerization at Asp23 reveals a distinct protofilament interface. Nature Communications, 2019, 10, 3357.	5.8	45
81	Dual Bioorthogonal Labeling of the Amyloid-Î² Protein Precursor Facilitates Simultaneous Visualization of the Protein and Its Cleavage Products. Journal of Alzheimer's Disease, 2019, 72, 537-548.	1.2	13
82	Female Sex Hormones and Cardiac Pressure Overload Independently Contribute to the Cardiogenic Dementia Profile in Yucatan Miniature Swine. Frontiers in Cardiovascular Medicine, 2019, 6, 129.	1.1	7
83	Effect of Post-Translational Modifications and Mutations on Amyloid-Î² Fibrils Dynamics at NÂTerminus. Biophysical Journal, 2019, 117, 1524-1535.	0.2	15
84	Seeding and Cross-Seeding Aggregations of AÎ²₄₀ and Its N-Terminal-Truncated Peptide AÎ²_{11â€“40}. Langmuir, 2019, 35, 2821-2831.	1.6	13
85	Trafficking and proteolytic processing of amyloid precursor protein and secretases in Alzheimer's disease development: An up-to-date review. European Journal of Pharmacology, 2019, 856, 172415.	1.7	64
86	Regulation of the alternative Î²-secretase meprin Î² by ADAM-mediated shedding. Cellular and Molecular Life Sciences, 2019, 76, 3193-3206.	2.4	19
87	Molecular structure of an N-terminal phosphorylated Î²-amyloid fibril. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 11253-11258.	3.3	43
88	Structure-Based Peptide Inhibitor Design of Amyloid-Î² Aggregation. Frontiers in Molecular Neuroscience, 2019, 12, 54.	1.4	58
89	The antiâ€prion RNA aptamer R12 disrupts the Alzheimer's diseaseâ€related complex between prion and amyloid Î². FEBS Journal, 2019, 286, 2355-2365.	2.2	9
90	Systematically Characterize the Anti-Alzheimer's Disease Mechanism of Lignans from S. chinensis based on In-Vivo Ingredient Analysis and Target-Network Pharmacology Strategy by UHPLCâ€“Q-TOF-MS. Molecules, 2019, 24, 1203.	1.7	21

#	Article	IF	Citations
91	Coimmunocapture and Electrochemical Quantitation of Total and Phosphorylated Amyloid-Î²₄₀ Monomers. Analytical Chemistry, 2019, 91, 3539-3545.	3.2	23
92	Solid-state NMR reveals a comprehensive view of the dynamics of the flexible, disordered N-terminal domain of amyloid-Î² fibrils. Journal of Biological Chemistry, 2019, 294, 5840-5853.	1.6	24
93	Cross-species genetic screens to identify kinase targets for APP reduction in Alzheimer's disease. Human Molecular Genetics, 2019, 28, 2014-2029.	1.4	5
94	Neuro biomarker levels measured with high-sensitivity digital ELISA differ between serum and plasma. Bioanalysis, 2019, 11, 2087-2094.	0.6	23
95	Emerging roles of N- and C-terminally truncated AÎ² species in Alzheimerâ€™s disease. Expert Opinion on Therapeutic Targets, 2019, 23, 991-1004.	1.5	32
96	The metalloprotease ADAMTS4 generates N-truncated AÎ²4â€“x species and marks oligodendrocytes as a source of amyloidogenic peptides in Alzheimerâ€™s disease. Acta Neuropathologica, 2019, 137, 239-257.	3.9	44
97	Amyloid precursor proteinâ€mediated mitochondrial regulation and Alzheimer's disease. British Journal of Pharmacology, 2019, 176, 3464-3474.	2.7	28
98	Intracerebroventricular injection of resveratrol ameliorated AÎ²-induced learning and cognitive decline in mice. Metabolic Brain Disease, 2019, 34, 257-266.	1.4	58
99	Amyloid-Î² and Parkinsonâ€™s disease. Journal of Neurology, 2019, 266, 2605-2619.	1.8	79
100	A vaccine against Alzheimer`s disease: anything left but faith?. Expert Opinion on Biological Therapy, 2019, 19, 73-78.	1.4	27
101	Complete identification of all 20 relevant epimeric peptides in Î²-amyloid: a new HPLC-MS based analytical strategy for Alzheimer's research. Chemical Communications, 2020, 56, 1537-1540.	2.2	20
102	Proteomic and Unbiased Post-Translational Modification Profiling of Amyloid Plaques and Surrounding Tissue in a Transgenic Mouse Model of Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 73, 393-411.	1.2	9
103	Phosphorylation Signaling in APP Processing in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 209.	1.8	51
104	From Stroke to Dementia: a Comprehensive Review Exposing Tight Interactions Between Stroke and Amyloid-Î² Formation. Translational Stroke Research, 2020, 11, 601-614.	2.3	82
105	Computational Analysis of Alzheimer Amyloid Plaque Composition in 2D- and Elastically Reconstructed 3D-MALDI MS Images. Analytical Chemistry, 2020, 92, 14484-14493.	3.2	15
106	Fast Purification of Recombinant Monomeric Amyloid-Î² from E. coli and Amyloid-Î²-mCherry Aggregates from Mammalian Cells. ACS Chemical Neuroscience, 2020, 11, 3204-3213.	1.7	4
107	Kinetic fingerprints differentiate the mechanisms of action of anti-AÎ² antibodies. Nature Structural and Molecular Biology, 2020, 27, 1125-1133.	3.6	123
108	Caenorhabditis elegans as a possible model to screen anti-Alzheimer's therapeutics. Journal of Pharmacological and Toxicological Methods, 2020, 106, 106932.	0.3	14

#	Article	IF	Citations
109	Flavonoids as BACE1 inhibitors: QSAR modelling, screening and in vitro evaluation. International Journal of Biological Macromolecules, 2020, 165, 1323-1330.	3.6	15
110	Structural characteristics of oligomers formed by pyroglutamate-modified amyloid Î² peptides studied by solid-state NMR. Physical Chemistry Chemical Physics, 2020, 22, 16887-16895.	1.3	11
111	N-Terminal Modified AÎ² Variants Enable Modulations to the Structures and Cytotoxicity Levels of Wild-Type AÎ² Fibrils through Cross-Seeding. ACS Chemical Neuroscience, 2020, 11, 2058-2065.	1.7	10
112	Analyzing microglial-associated AÎ² in Alzheimerâ€™s disease transgenic mice with a novel mid-domain AÎ²-antibody. Scientific Reports, 2020, 10, 10590.	1.6	3
113	Targeting isoaspartate-modified AÎ² rescues behavioral deficits in transgenic mice with Alzheimerâ€™s disease-like pathology. Alzheimer's Research and Therapy, 2020, 12, 149.	3.0	10
114	The existence of AÎ² strains and their potential for driving phenotypic heterogeneity in Alzheimerâ€™s disease. Acta Neuropathologica, 2021, 142, 17-39.	3.9	35
115	The coarse-grained plaque: a divergent AÎ² plaque-type in early-onset Alzheimerâ€™s disease. Acta Neuropathologica, 2020, 140, 811-830.	3.9	45
116	Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review. Journal of the Neurological Sciences, 2020, 415, 116886.	0.3	13
117	Dynamics of Serine-8 Side-Chain in Amyloid-Î² Fibrils and Fluorenylmethyloxycarbonyl Serine Amino Acid, Investigated by Solid-State Deuteron NMR. Journal of Physical Chemistry B, 2020, 124, 4723-4731.	1.2	3
118	Biophysical studies of protein misfolding and aggregation inin vivomodels of Alzheimer's and Parkinson's diseases. Quarterly Reviews of Biophysics, 2020, 53, e22.	2.4	13
119	Nâ€terminal heterogeneity of parenchymal and vascular amyloidâ€Î² deposits in Alzheimerâ€™s disease. Neuropathology and Applied Neurobiology, 2020, 46, 673-685.	1.8	20
120	Effects of N-Terminal Residues on the Assembly of Constrained Î²-Hairpin Peptides Derived from AÎ². Journal of the American Chemical Society, 2020, 142, 11593-11601.	6.6	12
121	Incorporation of the Nonproteinogenic Amino Acid Î²-Methylamino-alanine Affects Amyloid Î² Fibril Properties and Toxicity. ACS Chemical Neuroscience, 2020, 11, 1038-1047.	1.7	15
122	Computational Model to Unravel the Function of Amyloid-Î² Peptides in Contact with a Phospholipid Membrane. Journal of Physical Chemistry B, 2020, 124, 3300-3314.	1.2	7
123	Application of electrochemical method to a comparative study of spontaneous aggregation of amyloid-Î² isoforms. Journal of Electroanalytical Chemistry, 2020, 861, 113938.	1.9	7
124	Polyphenols as Potential Metal Chelation Compounds Against Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 82, S335-S357.	1.2	65
125	Amyloid-Î², tau, and the cholinergic system in Alzheimerâ€™s disease: seeking direction in a tangle of clues. Reviews in the Neurosciences, 2020, 31, 391-413.	1.4	56
126	Halogenation of the N â€Terminus Tyrosine 10 Promotes Supramolecular Stabilization of the Amyloidâ€Î² Sequence 7â€“12. ChemistryOpen, 2020, 9, 253-260.	0.9	6

#	Article	IF	Citations
127	Enhanced self-assembly of the 7â€“12 sequence of amyloid-Î² peptide by tyrosine bromination. Supramolecular Chemistry, 2020, 32, 247-255.	1.5	8
128	FAM222A encodes a protein which accumulates in plaques in Alzheimerâ€™s disease. Nature Communications, 2020, 11, 411.	5.8	16
129	PI3K activation prevents AÎ²42-induced synapse loss and favors insoluble amyloid deposit formation. Molecular Biology of the Cell, 2020, 31, 244-260.	0.9	8
130	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2020, 74, 1189-1201.	1.2	38
131	Impact of Nâ€Truncated AÎ² Peptides on Cuâ€and Cu(AÎ²)â€Generated ROS: Cu^I Matters!. Chemistry - A European Journal, 2021, 27, 1777-1786.	1.7	21
132	Functions of amyloid precursor protein in metabolic diseases. Metabolism: Clinical and Experimental, 2021, 115, 154454.	1.5	38
133	The Aggregation Pattern of AÎ²_{1â€“40} is Altered by the Presence of Nâ€Truncated AÎ²_{4â€“40} and/or Cu^{II} in a Similar Way through Ionic Interactions. Chemistry - A European Journal, 2021, 27, 2798-2809.	1.7	12
134	Drug design targeting active posttranslational modification protein isoforms. Medicinal Research Reviews, 2021, 41, 1701-1750.	5.0	33
135	Microbiota modulation as preventative and therapeutic approach in Alzheimerâ€™s disease. FEBS Journal, 2021, 288, 2836-2855.	2.2	60
136	Reproducibility Problems of Amyloid-Î² Self-Assembly and How to Deal With Them. Frontiers in Chemistry, 2020, 8, 611227.	1.8	13
137	Insights Into the Mechanism of Tyrosine Nitration in Preventing Î²-Amyloid Aggregation in Alzheimerâ€™s Disease. Frontiers in Molecular Neuroscience, 2021, 14, 619836.	1.4	4
139	Quantification of N-terminal amyloid-Î² isoforms reveals isomers are the most abundant form of the amyloid-Î² peptide in sporadic Alzheimerâ€™s disease. Brain Communications, 2021, 3, fcab028.	1.5	25
140	Probing the Structure of Toxic Amyloid-Î² Oligomers with Electron Spin Resonance and Molecular Modeling. ACS Chemical Neuroscience, 2021, 12, 1150-1161.	1.7	9
141	Racemization in Post-Translational Modifications Relevance to Protein Aging, Aggregation and Neurodegeneration: Tip of the Iceberg. Symmetry, 2021, 13, 455.	1.1	9
142	Mitochondrial Permeability Transition: A Pore Intertwines Brain Aging and Alzheimerâ€™s Disease. Cells, 2021, 10, 649.	1.8	27
143	Cerebellar Calcium-Binding Protein and Neurotrophin Receptor Defects in Down Syndrome and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 645334.	1.7	10
144	Inhibitory mechanism of an antifungal drug, caspofungin against amyloid Î² peptide aggregation: Repurposing via neuroinformatics and an experimental approach. Molecular and Cellular Neurosciences, 2021, 112, 103612.	1.0	3
145	In vivo Characterization of Biochemical Variants of Amyloid-Î² in Subjects with Idiopathic Normal Pressure Hydrocephalus and Alzheimerâ€™s Disease Neuropathological Change. Journal of Alzheimer's Disease, 2021, 80, 1003-1012.	1.2	3

#	Article	IF	Citations
146	The Diagnostic Potential of Amyloidogenic Proteins. International Journal of Molecular Sciences, 2021, 22, 4128.	1.8	7
147	AÎ²43 aggregates exhibit enhanced prion-like seeding activity in mice. Acta Neuropathologica Communications, 2021, 9, 83.	2.4	14
148	Refining the amyloid Î² peptide and oligomer fingerprint ambiguities in Alzheimerâ€™s disease: Mass spectrometric molecular characterization in brain, cerebrospinal fluid, blood, and plasma. Journal of Neurochemistry, 2021, 159, 234-257.	2.1	8
149	The complexity of Alzheimerâ€™s disease: an evolving puzzle. Physiological Reviews, 2021, 101, 1047-1081.	13.1	110
150	Differential interaction with <scp>TREM2</scp> modulates microglial uptake of modified AÎ² species. Glia, 2021, 69, 2917-2932.	2.5	9
151	Cross-Seeded Fibrillation Induced by Pyroglutamate-3 and Truncated AÎ²₄₀ Variants Leads to AÎ²₄₀ Structural Polymorphism Modulation and Elevated Toxicity. ACS Chemical Neuroscience, 2021, 12, 3625-3637.	1.7	11
152	The Absence of Myelin Basic Protein Reduces Non-Amyloidogenic Processing of Amyloid Precursor Protein. Current Alzheimer Research, 2021, 18, 326-334.	0.7	3
154	Modulation of Insulin Sensitivity by Insulin-Degrading Enzyme. Biomedicines, 2021, 9, 86.	1.4	35
157	Functional Amyloids and their Possible Influence on Alzheimer Disease. Discoveries, 2017, 5, e79.	1.5	9
158	AÎ² Plaques. Free Neuropathology, 2020, 1, .	2.4	21
159	Inhalational Anesthetics Do Not Deteriorate Amyloid-Î²-Derived Pathophysiology in Alzheimerâ€™s Disease: Investigations on the Molecular, Neuronal, and Behavioral Level. Journal of Alzheimer's Disease, 2021, 84, 1193-1218.	1.2	1
160	TREM2 modulates differential deposition of modified and non-modified AÎ² species in extracellular plaques and intraneuronal deposits. Acta Neuropathologica Communications, 2021, 9, 168.	2.4	12
161	The cellular modifier MOAGâ€4/SERF drives amyloid formation through charge complementation. EMBO Journal, 2021, 40, e107568.	3.5	15
163	Imaging Modalities: Neuropathology. , 2019, , 57-118.		0
164	Neurodegeneration: General Aspects. , 2019, , 827-870.		0
165	The New Insight for Novel Antimicrobial Peptides Designing by Computational Design and Improvement of an Antimicrobial Peptide Derivate of LL-37. Avicenna Journal of Clinical Microbiology and Infection, 2019, 6, 15-20.	0.2	2
168	Neurotoxicity of different amyloid beta subspecies in mice and their interaction with isoflurane anaesthesia. PLoS ONE, 2020, 15, e0242989.	1.1	5
169	Deuterium solidâ€state NMR quadrupolar order rotating frame relaxation with applications to amyloidâ€Î²2 fibrils. Magnetic Resonance in Chemistry, 2021, 59, 853-863.	1.1	2

#	Article	IF	Citations
170	Regulation of Neurodegeneration-associated Protein Fragments by the N-degron Pathways. Neurotoxicity Research, 2022, 40, 298-318.	1.3	5
172	Selected Natural Products in Neuroprotective Strategies for Alzheimerâ€™s Diseaseâ€”A Non-Systematic Review. International Journal of Molecular Sciences, 2022, 23, 1212.	1.8	6
173	Downregulation of PIK3CB Involved in Alzheimerâ€™s Disease via Apoptosis, Axon Guidance, and FoxO Signaling Pathway. Oxidative Medicine and Cellular Longevity, 2022, 2022, 1-15.	1.9	5
174	Relationship between Plasma Level of Beta-amyloid, Alpha-synuclein, and Tau Protein with Cognitive Impairment in Parkinson Disease. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 663-667.	0.1	2
175	Meprin Î² knockout reduces brain AÎ² levels and rescues learning and memory impairments in the APP/lon mouse model for Alzheimerâ€™s disease. Cellular and Molecular Life Sciences, 2022, 79, 168.	2.4	3
176	Physical Exercise, a Potential Non-Pharmacological Intervention for Attenuating Neuroinflammation and Cognitive Decline in Alzheimerâ€™s Disease Patients. International Journal of Molecular Sciences, 2022, 23, 3245.	1.8	13
177	Mass spectrometric studies of the variety of betaâ€amyloid proteoforms in Alzheimer's disease. Mass Spectrometry Reviews, 2022, , e21775.	2.8	7
178	Alzheimerâ€™s Disease: Current Perspectives and Advances in Physiological Modeling. Bioengineering, 2021, 8, 211.	1.6	6
179	The Dynamics of Î²-Amyloid Proteoforms Accumulation in the Brain of a 5xFAD Mouse Model of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 27.	1.8	7
180	Amyloid Î², Tau, and Î±-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Progress in Neurobiology, 2022, 214, 102270.	2.8	77
183	A Chemical Mutagenesis Approach to Insert Post-translational Modifications in Aggregation-Prone Proteins. ACS Chemical Neuroscience, 2022, 13, 1714-1718.	1.7	1
184	Electrochemical Aptasensors for Parkinsonâ€™s Disease Biomarkers Detection. Current Medicinal Chemistry, 2022, 29, 5795-5814.	1.2	2
186	Amyloid Beta Peptide-Mediated Alterations in Mitochondrial Dynamics and its Implications for Alzheimerâ€™s Disease. CNS and Neurological Disorders - Drug Targets, 2023, 22, 1039-1056.	0.8	1
187	Establishing In-House Cutoffs of CSF Alzheimerâ€™s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. International Journal of Molecular Sciences, 2022, 23, 6891.	1.8	13
189	Proteomic Markers and Early Prediction of Alzheimerâ€™s Disease. Biochemistry (Moscow), 2022, 87, 762-776.	0.7	2
190	Inhibition of PLK2 activity affects APP and tau pathology and improves synaptic content in a sex-dependent manner in a 3xTg mouse model of Alzheimer's disease. Neurobiology of Disease, 2022, 172, 105833.	2.1	3
191	Post-translational Modifications in Brain Diseases: A Future for Biomarkers. Advances in Experimental Medicine and Biology, 2022, , 129-141.	0.8	0
192	Altered glucose metabolism in Alzheimer's disease: Role of mitochondrial dysfunction and oxidative stress. Free Radical Biology and Medicine, 2022, 193, 134-157.	1.3	46

#	Article	IF	Citations
193	Pathophysiology of Alzheimerâ€™s Disease. Psychiatric Clinics of North America, 2022, , .	0.7	9
194	Mixed Pathologies in a Subject with a Novel PSEN1 G206R Mutation. Journal of Alzheimer's Disease, 2022, 90, 1601-1614.	1.2	1
195	The Hidden Role of Non-Canonical Amyloid Î² Isoforms in Alzheimerâ€™s Disease. Cells, 2022, 11, 3421.	1.8	3
196	Amyloid Beta in Aging and Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 12924.	1.8	50
197	Structural Determinant of Î²-Amyloid Formation: From Transmembrane Protein Dimerization to Î²-Amyloid Aggregates. Biomedicines, 2022, 10, 2753.	1.4	8
198	Targeting amyloid proteins for clinical diagnosis of neurodegenerative diseases. Fundamental Research, 2023, 3, 505-519.	1.6	4
199	Distinct Effects of Beta-Amyloid, Its Isomerized and Phosphorylated Forms on the Redox Status and Mitochondrial Functioning of the Bloodâ€“Brain Barrier Endothelium. International Journal of Molecular Sciences, 2023, 24, 183.	1.8	6
202	Phosphorylation and Dephosphorylation of Beta-Amyloid Peptide in Model Cell Cultures: The Role of Cellular Protein Kinases and Phosphatases. Life, 2023, 13, 147.	1.1	2
203	Jacobâ€induced transcriptional inactivation of <scp>CREB</scp> promotes AÎ²â€induced synapse loss in Alzheimer's disease. EMBO Journal, 2023, 42, .	3.5	9
204	Aggregation of Disordered Proteins Associated with Neurodegeneration. International Journal of Molecular Sciences, 2023, 24, 3380.	1.8	16
205	Mixed pathology as a rule, not exception: Time to reconsider disease nosology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 57-71.	1.0	6
206	Structural polymorphism and cytotoxicity of brainâ€derived Î²â€amyloid extracts. Protein Science, 2023, 32, .	3.1	4
207	Protein Interactome of Amyloid-Î² as a Therapeutic Target. Pharmaceuticals, 2023, 16, 312.	1.7	4
208	How Single Site Mutations Can Help Understanding Structure Formation of Amyloid Î²_{1â^'40}. Macromolecular Bioscience, 2023, 23, .	2.1	3
209	AÎ²₈₋₂₀ Fragment as an Anti-Fibrillogenic and Neuroprotective Agent: Advancing toward Efficient Alzheimerâ€™s Disease Treatment. ACS Chemical Neuroscience, 2023, 14, 1126-1136.	1.7	3
210	Mass Spectrometry Imaging in Alzheimer's Disease. Brain Connectivity, 2023, 13, 319-333.	0.8	4
211	Alleviating the unwanted effects of oxidative stress on AÎ² clearance: a review of related concepts and strategies for the development of computational modelling. Translational Neurodegeneration, 2023, 12, .	3.6	2
212	Alzheimerâ€™s Disease and Alzheimerâ€™s Disease-Related Dementias in African Americans: Focus on Caregivers. Healthcare (Switzerland), 2023, 11, 868.	1.0	2

#	Article	IF	Citations
213	Effect of Cross-Seeding of Wild-Type Amyloid-Î²_{1â€“40} Peptides with Post-translationally Modified Fibrils on Internal Dynamics of the Fibrils Using Deuterium Solid-State NMR. Journal of Physical Chemistry B, 2023, 127, 2887-2899.	1.2	3
215	Brain Region-Specific Differences in Amyloid-Î² Plaque Composition in 5XFAD Mice. Life, 2023, 13, 1053.	1.1	3
216	Clinical Peptidomics: Advances in Instrumentation, Analyses, and Applications. BME Frontiers, 2023, 4, .	2.2	5
219	Copper trafficking system in cells: insights into coordination chemistry and toxicity. Dalton Transactions, 0, , .	1.6	0